We are addressing challenges faced by families of children with rare diseases who are seeking a diagnosis, and our solution is a two-sided marketplace for rare disease genomic insights.
On one side, we will offer children who have a rare disease—and an inconclusive whole genome assay—another chance at a diagnosis. A majority of families who order a whole genome test do not receive their much needed diagnosis and are rarely provided with clear followup options. On the other side of the market, we will use the genomic data we collect to identify orphan drug leads, which we will sell to biopharma clients who are creating personalized medicines.
I'm happy to chat about any questions or comments you have!